| P50 | author | Adriana Zingone | Q23498559 |
| | Ola Landgren | Q66432182 |
| | Wendy Dubois | Q67472636 |
| P2093 | author name string | Jing Huang | |
| | W Michael Kuehl | |
| | Joy Gary | |
| | Ke Zhang | |
| | Maxwell P Lee | |
| | Aleksandra M Michalowski | |
| | Beverly A Mock | |
| | Elena Leon | |
| | John K Simmons | |
| | Shuling Zhang | |
| | Jin-Qiu Chen | |
| | Peter Ordentlich | |
| | Jyoti Patel | |
| | Nicholas Watson | |
| | Daniel Connors | |
| | Snehal Gaikwad | |
| | Benjamin J Gamache | |
| P2860 | cites work | Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma | Q24296639 |
| | Global mapping of c-Myc binding sites and target gene networks in human B cells | Q24675083 |
| | Semi-supervised methods to predict patient survival from gene expression data | Q24804682 |
| | Everolimus in the Treatment of Metastatic Breast Cancer | Q26784920 |
| | Network-based approaches in drug discovery and early development | Q26827940 |
| | Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 | Q28085004 |
| | BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 |
| | c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells | Q28275988 |
| | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 |
| | Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles | Q29617464 |
| | A general framework for weighted gene co-expression network analysis | Q29617580 |
| | Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma | Q33410761 |
| | Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines | Q33843555 |
| | Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. | Q34020965 |
| | Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? | Q34174883 |
| | Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy | Q34263870 |
| | Transcriptional amplification in tumor cells with elevated c-Myc. | Q34302542 |
| | The molecular classification of multiple myeloma | Q34530992 |
| | Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. | Q34714933 |
| | Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors | Q35071179 |
| | Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. | Q35204486 |
| | mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells | Q35273390 |
| | Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression | Q35805318 |
| | The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. | Q35953399 |
| | Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. | Q36204839 |
| | AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements | Q36229165 |
| | Strategies for optimizing combinations of molecularly targeted anticancer agents | Q36554418 |
| | Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function | Q36580032 |
| | Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents | Q36645808 |
| | Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors | Q36919101 |
| | Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a | Q36938662 |
| | The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology | Q36971433 |
| | Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system | Q37247078 |
| | TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms | Q37672563 |
| | Proteolytic control of the oncoprotein transcription factor Myc. | Q37894329 |
| | MYC degradation | Q38193043 |
| | Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis | Q38351001 |
| | Myc: the beauty and the beast | Q38568550 |
| | Panobinostat for the Treatment of Multiple Myeloma. | Q38585438 |
| | PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. | Q39120295 |
| | AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression | Q40623520 |
| | Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 | Q42152675 |
| | Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients | Q43007234 |
| | Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. | Q50904356 |
| | Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. | Q52096758 |
| | A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 |
| | High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients | Q57274902 |
| | Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling | Q58050821 |
| | Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M | Q58051897 |
| | The statistics of synergism | Q74591572 |
| | Mechanisms of drug combinations: interaction and network perspectives | Q83265745 |
| P433 | issue | 9 | |
| P304 | page(s) | 2008-2021 | |
| P577 | publication date | 2017-05-18 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. | |
| P478 | volume | 16 | |